Operating Leverage Inflection
What: New Unit Breakeven: Q1 FY27
Impact: Margin expansion
“Because all the doctors, all the fixed costs already been done... the losses only should come down.”
In , Krishna Institute of Medical Sciences Ltd (Hospitals) is outperforming Nifty 500 with +21.9% relative strength. Fundamentals: Weak. On a 5-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: New Unit Breakeven: Q1 FY27
Impact: Margin expansion
“Because all the doctors, all the fixed costs already been done... the losses only should come down.”
What: Hospital Count: 25 hospitals
“We now have 25 hospitals across 5 states... launched 7 hospitals in 2025.”
What: Transplant Volume: 25 in 3 months
“At KIMS Mahadevapura, Bangalore, 25 transplants were performed just within 3 months, which started functioning.”
What: Net Debt: ₹2,850 Cr
“I think moving forward, we may not see any incremental debt will be there on the books, and it will start coming down.”
What: CGHS Empanelment: Nashik/Thane
“We got empanelment of CGHS -- sorry ECHS in Nashik, we should start being able to take patients from next month.”
What: Revenue crossed ₹1,000 Cr mark
“I'm happy to share that this is a record-breaking quarter with the highest-ever revenue crossing the INR1,000 crores mark.”
Earnings deceleration risks from management commentary
Trigger: Dispute with the state government over payments led to a ban on taking scheme patients.
Management view: January volumes have bounced back to Q2 levels.
Monitor: regulatory
Trigger: Doctors fear their business will be impacted if the hospital is not empanelled with major payers.
Management view: Onboarding is now 90% complete in Thane; Bangalore has 200 doctors.
Monitor: labor
Key quotes from recent conference calls
“we will break even in the next 2 months based on how things are going in the last few months. [Previous Thane & Mahadevapura Breakeven guidance]”
“KIMS entered into an agreement with Andrea Saba for its land to construct and operate a hospital at Chennai for 26 years. [Initiative: Chennai Hospital Construction]”
“As far as Andhra, in quarter 3, we had a strike with the state government. So we had not taken Aarogyasri scheme for almost a month. [Risk (regulatory): MEDIUM]”
“we are finding it difficult for all the doctors who have committed to come and join KIMS to join before this empanelment is done. [Risk (labor): LOW]”
Headline numbers from the latest earnings call
Revenue
₹1,003 Cr
Why: Record-breaking quarter crossing the ₹1,000 crore mark despite Q3 traditionally being a weak quarter due to inherent strength and enhanced network.
Revenue growth was driven by new units despite initial pressures.
EBITDA
₹204 Cr
Why: Decline in EBITDA was mainly on account of EBITDA erosion caused by the newer units that commenced operations over the last 9 to 12 months.
Margins compressed from 25.9% to 20.4% YoY as new assets ramp up.
PAT
₹52 Cr
Why: Impacted by EBITDA erosion from new units and higher depreciation/interest costs associated with the expansion phase.
PAT saw a sharp decline due to the operational drag of newly commissioned hospitals.
Other Highlights
• Net debt stood at ₹2,850 Cr as of December 31, 2025.
• Cash and equivalents increased to ₹206 Cr.
• Launched 7 new hospitals in 2025 across 5 states.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Average Revenue Per Operating Bed
₹70,000 - ₹75,000
Why: Driven by high-end transplant work and entry into high-ARPOB markets like Mumbai and Bangalore.
In-Patient Volume
61,139
Why: QoQ decline due to the Aarogyasri strike in Andhra Pradesh and seasonal weakness.
Bed Occupancy Rate (Telangana)
52.5%
Why: Low reported occupancy due to 200-250 beds being under renovation in Secunderabad.
Average Revenue Per Patient
Not Given
Why: Improvement in case mix and higher specialty contribution.
Net Debt
₹2,850 Cr
Why: Reflects debt raised for the recent massive expansion phase.
Total Hospitals
25
Why: Aggressive expansion in 2025 across 5 states.
Karnataka Cluster ARPOB
₹76,000
Why: High due to significant transplant work in the initial months.
CGHS Revenue Contribution
10%
Why: Contribution from government health schemes in core clusters.
Forward-looking targets from management for 3 years
Revenue Growth Target
100%
Capex Plan
₹600 Cr
100% growth
EBITDA neutral/positive for new units by Q1 FY27
₹500-600 Cr
Full closure of ongoing projects
20-25% growth at new Kondapur facility
Guidance Changes
Debt Trajectory: Increasing → Peaked out
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +29% | +23% | Stable |
| PAT (Net Profit) | -43% | +6% | Inflection Down |
| OPM | 20.0% | -400 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Krishna Institute of Medical Sciences Ltd's latest quarterly results (Dec 2025) show
Krishna Institute of Medical Sciences Ltd's profit is declining with an inflecting downward trend.
Krishna Institute of Medical Sciences Ltd's revenue growth trend is stable.
Krishna Institute of Medical Sciences Ltd's operating margin is volatile.
Krishna Institute of Medical Sciences Ltd's long-term compounding rates
Krishna Institute of Medical Sciences Ltd's earnings growth is inflecting downward with negative momentum on a sequential basis.
Krishna Institute of Medical Sciences Ltd's trailing twelve month (TTM) performance
Krishna Institute of Medical Sciences Ltd appears significantly overvalued based on our fair value analysis.
Krishna Institute of Medical Sciences Ltd's current PE ratio is 97.9x.
Krishna Institute of Medical Sciences Ltd's current PE is 97.9x.
Krishna Institute of Medical Sciences Ltd's price-to-book ratio is 12.7x.
Krishna Institute of Medical Sciences Ltd is rated Weak with a fundamental score of 27.52/100. This score is calculated from objective financial metrics
Krishna Institute of Medical Sciences Ltd has a debt-to-equity ratio of N/A.
Krishna Institute of Medical Sciences Ltd's return ratios over recent years
Krishna Institute of Medical Sciences Ltd's operating cash flow is positive (FY2025).
Krishna Institute of Medical Sciences Ltd currently does not pay a significant dividend (yield 0.00%).
Krishna Institute of Medical Sciences Ltd's shareholding pattern (Mar 2026)
Krishna Institute of Medical Sciences Ltd's promoter holding has remained stable recently.
Krishna Institute of Medical Sciences Ltd has been outperforming Nifty 500 for 5 consecutive weeks, indicating building momentum.
Krishna Institute of Medical Sciences Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Krishna Institute of Medical Sciences Ltd has 6 key growth catalysts identified from recent earnings analysis
Krishna Institute of Medical Sciences Ltd has 2 key risks worth monitoring
In Q3 FY26, Krishna Institute of Medical Sciences Ltd's management highlighted
Krishna Institute of Medical Sciences Ltd's management has provided the following forward guidance for 3 years
Krishna Institute of Medical Sciences Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Krishna Institute of Medical Sciences Ltd may be worth studying
Krishna Institute of Medical Sciences Ltd investment thesis summary:
Krishna Institute of Medical Sciences Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.